USPTO serial 79315257
OMERO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 10, 2024
- Examiner
- MONINGHOFF, KIM TERESA
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with OMERO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
STACEY J. WATSON, ESQ.
STACEY J. WATSON, ESQ. MARKERY LAW LLCP.O. BOX 84150GAITHERSBURG, MD 20883-4150UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Computer software that is downloaded and installed for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; computer software downloadable from the Internet for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science;data access and data management software tools that are downloaded and installed for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; downloadable electronic publications in the nature of scientific journals, periodicals and newsletters relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof | ACTIVE | — |
| 035 | Business services relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science, namely, management of biological and biomedical data and images for business enterprises; data processing services relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; information, advisory and consultancy services in connection with the aforesaid services; none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof | ACTIVE | — |
| 042 | Design and development of computer software, data access and data management software tools for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; computer programming; installation, maintenance and repair of computer software; design of computer websites and maintenance thereof, all relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; software as a service (SAAS) featuring software for accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; information, advisory and consultancy services in connection with the aforesaid services; none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof | ACTIVE | — |
| 045 | Licensing of computer software for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; information, advisory and consultancy services in connection with the aforesaid services; none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Glencoe Software Inc.
- Other trademarks owned by Glencoe Software Inc.
- Other trademarks owned by Glencoe Software Inc.
- Other trademarks in Class 009
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 045
- Similar marks named OMERO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 9, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 18, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 18, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 10, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Sep 10, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 10, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 2, 2024 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Aug 2, 2024 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Aug 2, 2024 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| May 30, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 3, 2023 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| May 1, 2023 | OPNS | OPPOSITION NOTICE (IB REFUSAL) SENT TO IB | — |
| Apr 29, 2023 | OPNC | OPPOSITION NOTICE (IB REFUSAL) CREATED | — |
| Jan 3, 2023 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 14, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 14, 2022 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 14, 2022 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Nov 1, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Nov 1, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 1, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 12, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 12, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Oct 12, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 23, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 23, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 23, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 23, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 23, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 22, 2022 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| May 11, 2022 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| May 11, 2022 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 11, 2022 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 9, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 8, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 8, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 5, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 5, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 5, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 5, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 5, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 29, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 9, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 8, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 8, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 7, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 4, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 30, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 26, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 19, 2021 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jul 8, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |